Answers are grounded in this paper and cite their sources.
Stem cell research has reshaped human biology and opened new frontiers for regenerative medicine. Yet public and commercial enthusiasm has at times outpaced the evidence, leaving room for unproven and occasionally harmful interventions. This narrative review examines the roots of that gap. Stem cells are not autonomous repair kits: their behavior depends substantially on their microenvironment, and directing it reliably remains difficult. We contrast established therapy, notably hematopoietic stem cell transplantation, and emerging clinical successes, including pluripotent stem cell-derived retinal and dopaminergic grafts and gene-edited hematopoietic stem cells, with applications whose benefit remains unproven. We also consider how direct-to-consumer markets reach patients with few treatment options. Successful translation depends on the specific cell product, indication, manufacturing process and clinical context; lasting progress therefore rests on rigorous standards and transparent oversight rather than hype.
No takes yet. Share an insight, caveat, or question.
Le et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: